These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 8618242

  • 1. Paclitaxel premedication regimens.
    Boehm DK, Maksymiuk AW.
    J Natl Cancer Inst; 1996 Apr 03; 88(7):463-5. PubMed ID: 8618242
    [No Abstract] [Full Text] [Related]

  • 2. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
    Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP.
    Br J Cancer; 2004 Jan 26; 90(2):304-5. PubMed ID: 14974481
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
    Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, Parö G.
    Acta Oncol; 2002 Jan 26; 41(5):418-24. PubMed ID: 12442916
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Single-dose dexamethasone paclitaxel premedication.
    Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV.
    Gynecol Oncol; 1998 May 26; 69(2):122-4. PubMed ID: 9600818
    [Abstract] [Full Text] [Related]

  • 10. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF.
    Semin Oncol; 1997 Dec 26; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
    Slichenmyer WJ, Donehower RC, Chen TL, Bowling MK, McGuire WP, Rowinsky EK.
    Cancer Chemother Pharmacol; 1995 Dec 26; 36(3):227-32. PubMed ID: 7781143
    [Abstract] [Full Text] [Related]

  • 15. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
    Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CL.
    Support Care Cancer; 2012 Sep 26; 20(9):1991-7. PubMed ID: 22089428
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A feasibility study of 1-h paclitaxel infusion in patients with solid tumors.
    Tsavaris N, Polyzos A, Kosmas C, Giannikos L, Gogas J.
    Cancer Chemother Pharmacol; 1997 Sep 26; 40(4):353-7. PubMed ID: 9225955
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.